Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company's core business is operating steadily, focusing on refined management practices [1] - In 2024, the company achieved total revenue of 4.815 billion yuan, a year-on-year increase of 4.28%, while the net profit attributable to shareholders was a loss of 254.13 million yuan, narrowing by 31.01% compared to the previous year [7] - The company is in a growth phase, with expectations for revenue to reach 4.823 billion yuan in 2025 and 5.533 billion yuan in 2026 [1][7] Financial Performance Summary - Total revenue forecast for 2023A is 4.618 billion yuan, with a projected increase to 4.815 billion yuan in 2024A and 4.823 billion yuan in 2025E [1] - The net profit attributable to shareholders is expected to improve from a loss of 368.36 million yuan in 2023A to a loss of 254.13 million yuan in 2024A, and further to a loss of 219.54 million yuan in 2025E [1] - The earnings per share (EPS) is projected to improve from -0.16 yuan in 2023A to -0.11 yuan in 2024A and -0.10 yuan in 2025E [1] Business Operations Summary - The company reported a total of 2.5727 million outpatient and emergency service visits in 2024, a year-on-year increase of 7.70%, and 205,700 inpatient service visits, an increase of 10.73% [7] - The Xi'an High-tech Hospital achieved revenue of 1.525 billion yuan in 2024, with a net profit of 85 million yuan, reflecting a net profit margin of 5.6% [7] - The company is focusing on developing specialized services such as integrated Chinese and Western medicine, high-end health management, and assisted reproductive medicine, aiming to become one of the largest reproductive medicine centers in China [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's core business is operating steadily, focusing on refined management practices [1] - In 2024, the company achieved total revenue of 4.815 billion yuan, a year-on-year increase of 4.28%, while the net profit attributable to shareholders was a loss of 254.13 million yuan, narrowing by 31.01% [7] - The company is in a growth phase, with expectations for revenue to reach 4.823 billion yuan in 2025 and 5.533 billion yuan in 2026 [1][7] Financial Performance Summary - Total revenue projections for 2024, 2025, 2026, and 2027 are 4.815 billion yuan, 4.823 billion yuan, 5.533 billion yuan, and 6.147 billion yuan respectively [1] - The net profit attributable to shareholders is projected to improve from a loss of 254.13 million yuan in 2024 to a profit of 49.41 million yuan in 2027 [1] - The earnings per share (EPS) is expected to improve from -0.11 yuan in 2024 to 0.02 yuan in 2027 [1] Business Operations Summary - The company reported a total of 2.5727 million outpatient and emergency service visits in 2024, a year-on-year increase of 7.70%, and 205,700 inpatient service visits, an increase of 10.73% [7] - The Xi'an High-tech Hospital achieved revenue of 1.525 billion yuan in 2024, with a net profit of 85 million yuan, reflecting a net profit margin of 5.6% [7] - The company is focusing on developing specialized services such as integrated Chinese and Western medicine, high-end health management, and smart traditional Chinese medicine [7] Valuation and Future Outlook - The company's revenue forecasts for 2025 and 2026 have been adjusted down to 4.823 billion yuan and 5.533 billion yuan respectively, with a projected market value corresponding to price-to-sales (PS) ratios of 2.4 and 2.1 times [7] - The company is expected to gradually improve its valuation as its core hospital bed capacity increases [7]

Group 1 - The core viewpoint of the news is that Xi'an International Medical Investment Co., Ltd. reported its 2024 annual results, showing a slight increase in revenue but a net loss that has narrowed compared to the previous year [2] - In 2024, the company achieved an operating income of 4.815 billion yuan, representing a year-on-year growth of 4.28% [2] - The net profit attributable to shareholders was -254 million yuan, a year-on-year narrowing of 31.01%, while the net profit after deducting non-recurring gains and losses was -287 million yuan, narrowing by 42.50% [2] Group 2 - The company has developed an innovative business model of "comprehensive medical care + specialty departments" to meet diverse healthcare needs and leverage the synergy of comprehensive medical institutions [3] - International Medical has established several specialized departments, including neurology, cardiology, oncology, and orthopedics, and has successfully performed complex medical procedures, including multiple world-first and national-first surgeries [3] - The company is actively exploring and expanding into aesthetic medicine, rehabilitation, women's and children's health, traditional Chinese medicine, and other sectors to cater to the growing diverse health demands of the public [3] Group 3 - International Medical plans to collaborate with leading companies such as Huawei, Mindray, and BGI to promote digital transformation and technological innovation [4] - The company aims to enhance its core competitiveness and sustainable profitability, positioning itself as a leading health management group providing full lifecycle medical health services [4]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of International Medical Investment Co., Ltd, indicating a decline in revenue and net profit in the latest quarterly report [1] - As of March 31, 2025, the number of shareholders increased to 109,907, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company operates in the health care service sector and modern medical technology application, with various product lines including medical services, software and information technology services, and other social services [1] Group 2 - The latest financial results show a revenue of 999.7 million yuan for Q1 2025, representing a year-on-year decrease of 14.99%, and a net loss of approximately 106.35 million yuan, a decline of 1.37% year-on-year, with a gross profit margin of 5.21% [1] - The company's current price-to-earnings (P/E) ratio is -44.75, with a price-to-book (P/B) ratio of 3.21 and a total market capitalization of 11.438 billion yuan [2] - The industry average P/E ratio is 46.43, while the industry median P/E is 51.51, indicating that International Medical's valuation metrics are below industry averages [2]

Core Viewpoint - The company demonstrated strong operational resilience in a complex external environment, achieving steady revenue growth and significantly narrowing losses in its 2024 annual report [1] Financial Performance - The company reported a total revenue of 4.815 billion yuan, representing a year-on-year increase of 4.28% [1] - The net profit attributable to shareholders was -254 million yuan, a reduction in losses by 31.01% compared to the previous year, outperforming market expectations [1] Operational Efficiency - The company improved operational efficiency through continuous optimization, benefiting from its strategic focus on a "comprehensive medical + specialty" development model and "medical + health" service model [1] - The total number of outpatient and emergency services reached 2.5727 million visits, an increase of 7.70% year-on-year, while inpatient services grew by 10.73% to 205,700 visits [2] Service Capacity and Quality - The company’s various hospitals showed strong performance, with the Xi'an High-tech Hospital generating revenue of 1.525 billion yuan, up 2.68%, and a net profit of 84.76 million yuan, an increase of 21.63% [3] - The Central Hospital (including the North Campus) achieved revenue of 3.274 billion yuan, a 7.60% increase, while its net loss narrowed by 36.67% to -165 million yuan [3] Specialty Development - The company has developed a "comprehensive medical + specialty" innovative business model to meet diverse healthcare needs, establishing large specialty hospitals in various fields [4] - The company opened new specialty departments and expanded existing ones, enhancing its service capacity and optimizing its academic layout [5][6] Future Outlook - The company plans to leverage the opportunity of the tertiary hospital evaluation to drive quality development through institutional innovation, management reform, and technological updates [7] - With the release of new hospital capacities and the deepening of international strategies, the company is positioned to transition from traditional medical valuation to innovative medical valuation, warranting long-term attention [7]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000516 证券简称：国际医学 公告编号：2025-010 西安国际医学投资股份有限公司2024年年度报告摘要 一、重要提示 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者 应当到证监会指定媒体仔细阅读年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 □适用 √不适用 公司计划不派发现金红利，不送红股，不以公积金转增股本。 董事会决议通过的本报告期优先股利润分配预案 1、公司简介 ■ 2、报告期主要业务或产品简介 （一）主要业务 公司以大健康医疗服务和现代医学技术转化应用为主业。目前，正在运营西安高新医院、西安国际医学 中心医院等综合性医疗机构。在医疗领域，公司探索并发展了"综合医疗+特色专科"创新业务模式，旨 在满足广大群众多元化医疗健康需求，充分发掘综合性医疗机构的协同效应。一方面致力于提供高质量 普惠型医疗服务，成功打造了脑科、心血管、消化、胸科、肿瘤、血液病、骨科等多个优势专科，开展 了一系列技术含 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 □适用 √不适用 前10名股东及前10名无限售流通股股东因转融通出借/归还原因导致较上期发生变化 □适用 √不适用 （2） 公司优先股股东总数及前10名优先股股东持股情况表 □适用 √不适用 公司报告期无优先股股东持股情况。 （3） 以方框图形式披露公司与实际控制人之间的产权及控制关系 ■ 5、在年度报告批准报出日存续的债券情况 □适用 √不适用 三、重要事项 2024年4月19日，经公司执行委员会审议通过，本公司与陕西众和防务投资控股有限责任公司共同出资 2,000万元设立西安国际医学科技医疗有限公司，本公司认缴出资980万元，占该公司股权比例为49%， 陕西众和防务投资控股有限责任公司认缴出资1,020万元，占公司股权比例为51%，该公司于2024年6月 4日完成工商注册。 2024年9月10日，经公司执行委员会审议通过，同意注销公司控股子公司西安国柏健康管理有限公司。 西安国际医学投资股份有限公司董事会 董事长 史 今 二〇二五年四月二十三日 证券代码：000516 证券简称：国际医学 公告编号：2025-008 西安国际医学投资股份有限公司 第十三届董 ...

证券代码：000516 证券简称：国际医学 公告编号：2025-016 西安国际医学投资股份有限公司 关于使用自有闲置资金进行委托理财额度的公告 本公司及董事会全体成员保证公告内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 2025年4月21日，西安国际医学投资股份有限公司（以下简称"公 司"）召开第十三届董事会第五次会议审议通过了《关于使用自有闲 置资金进行委托理财额度的议案》。为进一步提升公司现有资金的使 用效率、提高资金收益，公司及所属子公司拟以闲置自有资金按照安 全、稳健的原则适时进行委托理财（含银行理财产品、信托产品等）。 投资额度5亿元，自公司董事会审议通过后12个月内滚动使用。根据《深 圳证券交易所股票上市规则》及《公司章程》有关规定，本次委托理 财事项无需提交股东大会审议。具体情况公告如下： 一、委托理财概述 1、委托理财的目的 为进一步提高经营资金的使用效率、合理利用闲置资金、提高资 金收益，在不影响公司及子公司正常经营的情况下，公司及所属子公 司拟以闲置自有资金按照安全、稳健的原则适时进行委托理财（含银 行理财产品、信托产品等）。 2、委托理财的额度 根据公司经营发展计划和 ...

西安国际医学投资股份有限公司 2024年度内部控制评价报告 2025年4月21日 2024年度内部控制评价报告 西安国际医学投资股份有限公司全体股东： 西安国际医学投资股份有限公司（以下简称"公司"）根据《企 业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求 （以下简称"企业内部控制规范体系"），结合本公司内部控制制度 和评价办法，在内部控制日常监督和专项监督的基础上，我们对公司 2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行 了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控 制，评价其有效性，并如实披露内部控制评价报告是公司董事会的责 任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、 高级管理人员保证本报告内容不存在任何虚假记载、误导性陈述或重 大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 二、内部控制评价结论 西安国际医学投资股份有限公司（000516） 2024 年度内部控制评价报告 西安国际医学投资股份有限公司 （一）内部控制评价范围 公 ...

证券代码：000516 证券简称：国际医学 公告编号：2025-013 西安国际医学投资股份有限公司 关于续聘会计师事务所的公告 本公司及董事会全体成员保证公告内容的真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 西安国际医学投资股份有限公司（以下简称"公司"）于2025年4月21日召 开第十三届董事会第五次会议，审议通过了《关于续聘中审亚太会计师事务所（特 殊普通合伙）的提案》，公司董事会拟续聘中审亚太会计师事务所（特殊普通合 伙）为公司2025年度财务报告及内部控制审计机构。现将有关事项公告如下： 截至 2024 年末，中审亚太拥有执业注册会计师 482 人，注册会计师中签署 过证券服务业务审计报告的注册会计师 180 余人。 中审亚太 2024 年度经审计的业务总收入 70,397.66 万元，其中，审计业务 收入 68,203.21 万元，证券业务收入 30,108.98 万元。2024 年度上市公司年报 审计客户共计 40 家，挂牌公司审计客户 183 家。2024 年度上市公司审计收费 1 6,069.23 万元，2024 年度挂牌公司审计收费 2,707.37 万元。2024 年度本公 ...